Corvus Pharmaceuticals announced on June 25, 2025, that its partner in China, Angel Pharmaceuticals Ltd., received IND approval from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA). This approval allows Angel Pharma to initiate a Phase 1b/2 clinical trial of soquelitinib for the treatment of moderate-to-severe atopic dermatitis in China.
The Angel Phase 1b/2 trial will further expand the clinical experience with soquelitinib in atopic dermatitis, incorporating a 12-week treatment period and a 400 mg once-daily dose. Patient enrollment for the trial is anticipated to commence in the third quarter of 2025, with data from the Phase 1b portion expected in 2026.
This IND approval represents a significant step in the global development of soquelitinib, opening access to the substantial Chinese market for atopic dermatitis. The additional clinical data from this trial will complement Corvus's ongoing studies and contribute to the overall understanding of soquelitinib's efficacy and safety profile.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.